Abbott has entered a licensing and supply agreement with Zydus Cadila of India for a portfolio of pharmaceutical products that Abbott will commercialize in 15 emerging markets. Abbott will gain rights to at least 24 products in 15 emerging markets. The agreement also includes an option for the addition of more than 40 Zydus products to the collaboration. These products include indications for pain, cancer and cardiovascular, neurological and respiratory diseases. The partnership will leverage Abbott’s infrastructure to commercialize the Zydus products, with product launches beginning in early 2012.

Abbott has created the Established Products Division (EPD), dedicated to expanding the market for its established pharmaceutical portfolio outside of the U.S., with an emphasis on emerging markets. EPD will be led by Michael J. Warmuth, who most recently led Abbott’s Diagnostics Division.

“Our new Established Products Division, with $5 billion in sales, will focus on expanding our presence and product offerings in the world’s fastest-growing emerging markets,” said Olivier Bohuon, executive vice president, Pharmaceutical Products Group, Abbott. EPD is part of the Pharmaceutical Products Group reporting to Mr. Bohuon.

“We have always believed in working with partners for win-win alliances that look at new opportunities for growth and expansion,” said Zydus Cadila chairman and managing director, Pankaj R. Patel. “In this alliance we see tremendous opportunity to participate in multiple ways in a market that is growing and expanding rapidly. Building on our mutual strengths we are creating a considerable competitive advantage for value creation for both partners over the long term.”